News & Updates

April 2, 2026

Clarametyx Biosciences Strengthens Executive Leadership to Accelerate Clinical Development Efforts

Read More
January 27, 2026

Clarametyx Biosciences Strengthens Scientific Advisory Board With Expert Appointments to Advance Pipeline Programs

Read More
January 9, 2026

Clarametyx Biosciences Announces Positive Topline Data from Phase 2a Study Evaluating CMTX-101 in Cystic Fibrosis

Read More
October 20, 2025

Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development Progress

Read More
October 16, 2025

Clarametyx Biosciences Announces Completion of Enrollment in Phase 2a Study of CMTX-101 in Cystic Fibrosis

Read More
August 4, 2025

Clarametyx Biosciences Announces FDA Grant of Fast Track And Qualified Infectious Disease Product Designations For CMTX-101

Read More
June 16, 2025

Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2a Study Evaluating CMTX-101 for Infections Associated with Cystic Fibrosis

Read More
May 2, 2025

CincyTech Invests in Clarametyx to Advance Breakthrough Anti-Biofilm Therapies for Chronic Respiratory Disease

Read More
January 28, 2025

Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund

Read More
Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.